CARsgen Therapeutics Holdings Ltd. (HK:2171) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CARsgen Therapeutics Holdings Ltd. announced promising results from a pivotal Phase II clinical trial for their CAR T-cell therapy, satricabtagene autoleucel, in treating advanced gastric and gastroesophageal junction cancers. The study demonstrated a statistically significant improvement in progression-free survival, positioning satri-cel as a potential first-in-class treatment. With this advancement, CARsgen continues to enhance its reputation in innovative cancer therapies, focusing on solid tumors.
For further insights into HK:2171 stock, check out TipRanks’ Stock Analysis page.